NCT00624026View on ClinicalTrials.gov

Memantine - Communication Study

PHASE3CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Alzheimer's Disease
Interventions
DRUG

Memantine-HCl

20 mg per day (once daily)

Trial Locations (1)

60318

Central Medical Affairs, Frankfurt am Main

Sponsors
All Listed Sponsors
lead

Merz Pharmaceuticals GmbH

INDUSTRY

NCT00624026 - Memantine - Communication Study | Biotech Hunter | Biotech Hunter